Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Margetuximab for the treatment of HER2-positive breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

The future of PARP inhibitors in metastatic breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

The future of PARP inhibitors in metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

A phase II study of bemcentinib with pembrolizumab in patients with advanced...

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2...

Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors in metastatic breast cancer: Where are we now?

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive...

Prof Hope Rugo - University of California, San Francisco, USA

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )

Preliminary results of earlier steroid use with axicabtagene ciloleucel in...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE)...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

POLO Trial: Olaparib as a maintenance treatment following first-line...

Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona...

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer ( Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until...

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

$Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )$

More from ecancer